A Two-gene Blood Test for Methylated DNA Sensitive for Colorectal Cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 May 1

PMID 25928810

Citations 32

Authors

Susanne K Pedersen

Rohan T Baker

Aidan McEvoy

David H Murray

Melissa Thomas

Peter L Molloy

Sue Mitchell

Trevor Lockett

Graeme P Young

Lawrence C LaPointe

Affiliations

Soon will be listed here.

Abstract

Background: Specific genes are methylated with high frequency in colorectal neoplasia, and may leak into blood. Detection of multiple methylated DNA biomarkers in blood may improve assay sensitivity for colorectal cancer (CRC) relative to a single marker. We undertook a case-control study evaluating the presence of two methylation DNA markers, BCAT1 and IKZF1, in circulation to determine if they were complementary for detection of CRC.

Methods: Methylation-specific PCR assays were developed to measure the level of methylated BCAT1 and IKZF1 in DNA extracted from plasma obtained from colonoscopy-confirmed 144 healthy controls and 74 CRC cases.

Results: DNA yields ranged from 2 to 730 ng/mL plasma (mean 18.6ng/mL; 95% CI 11-26 ng/mL) and did not correlate with gender, age or CRC status. Methylated BCAT1 and IKZF1 DNA were detected in respectively 48 (65%) and 50 (68%) of the 74 cancers. In contrast, only 5 (4%) and 7 (5%) controls were positive for BCAT1 and IKZF1 DNA methylation, respectively. A two-gene classifier model ("either or" rule) improved segregation of CRC from controls, with 57 of 74 cancers (77%) compared to only 11 of 144 (7.6%) controls being positive for BCAT1 and/or IKZF1 DNA methylation. Increasing levels of methylated DNA were observed as CRC stage progressed.

Conclusions: Detection of methylated BCAT1 and/or IKZF1 DNA in plasma may have clinical application as a novel blood test for CRC. Combining the results from the two methylation-specific PCR assays improved CRC detection with minimal change in specificity. Further validation of this two-gene blood test with a view to application in screening is now indicated.

Citing Articles

Molecular counting enables accurate and precise quantification of methylated ctDNA for tumor-naive cancer therapy response monitoring.

Ye P, Viens R, Shelburne K, Langpap S, Bower X, Shi J Sci Rep. 2025; 15(1):5869.

PMID: 39966612 PMC: 11836444. DOI: 10.1038/s41598-025-90013-3.

Ultrasensitive Amplification-Free Quantification of a Methyl CpG-Rich Cancer Biomarker by Single-Molecule Kinetic Fingerprinting.

Dai L, Johnson-Buck A, Laird P, Tewari M, Walter N Anal Chem. 2024; 96(43):17209-17216.

PMID: 39425638 PMC: 11648273. DOI: 10.1021/acs.analchem.4c03002.

DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine.

Ye J, Zhang J, Ding W Explor Target Antitumor Ther. 2024; 5(1):34-53.

PMID: 38464391 PMC: 10918240. DOI: 10.37349/etat.2024.00203.

Diagnostic value of methylated branched chain amino acid transaminase 1/IKAROS family zinc finger 1 for colorectal cancer.

Xu K, Yu A, Pan S, He J World J Gastroenterol. 2023; 29(36):5240-5253.

PMID: 37901447 PMC: 10600955. DOI: 10.3748/wjg.v29.i36.5240.

Evaluation of epigenetic methylation biomarkers for the detection of colorectal cancer using droplet digital PCR.

Petit J, Carroll G, Zhao J, Roper E, Pockney P, Scott R Sci Rep. 2023; 13(1):8883.

PMID: 37264006 PMC: 10235040. DOI: 10.1038/s41598-023-35631-5.

References

Wang W, Goswami S, Sahai E, Wyckoff J, Segall J, Condeelis J . Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol. 2005; 15(3):138-45. DOI: 10.1016/j.tcb.2005.01.003. View

Riccio O, van Gijn M, Bezdek A, Pellegrinet L, van Es J, Zimber-Strobl U . Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2. EMBO Rep. 2008; 9(4):377-83. PMC: 2288761. DOI: 10.1038/embor.2008.7. View

Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S . Notch signals control the fate of immature progenitor cells in the intestine. Nature. 2005; 435(7044):964-8. DOI: 10.1038/nature03589. View

Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S . Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005; 102(45):16368-73. PMC: 1283450. DOI: 10.1073/pnas.0507904102. View

Koukourakis M, Giatromanolaki A, Sivridis E, Gatter K, Harris A . Inclusion of vasculature-related variables in the Dukes staging system of colon cancer. Clin Cancer Res. 2005; 11(24 Pt 1):8653-60. DOI: 10.1158/1078-0432.CCR-05-1464. View

Radtke F, Clevers H, Riccio O . From gut homeostasis to cancer. Curr Mol Med. 2006; 6(3):275-89. DOI: 10.2174/156652406776894527. View

Yoshikawa R, Yanagi H, Shen C, Fujiwara Y, Noda M, Yagyu T . ECA39 is a novel distant metastasis-related biomarker in colorectal cancer. World J Gastroenterol. 2006; 12(36):5884-9. PMC: 4100673. DOI: 10.3748/wjg.v12.i36.5884. View

Gormally E, Caboux E, Vineis P, Hainaut P . Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res. 2007; 635(2-3):105-117. DOI: 10.1016/j.mrrev.2006.11.002. View

Staton C, Chetwood A, Cameron I, Cross S, Brown N, Reed M . The angiogenic switch occurs at the adenoma stage of the adenoma carcinoma sequence in colorectal cancer. Gut. 2007; 56(10):1426-32. PMC: 2000239. DOI: 10.1136/gut.2007.125286. View

10.

Sridharan R, Smale S . Predominant interaction of both Ikaros and Helios with the NuRD complex in immature thymocytes. J Biol Chem. 2007; 282(41):30227-38. DOI: 10.1074/jbc.M702541200. View

11.

Grutzmann R, Molnar B, Pilarsky C, Habermann J, Schlag P, Saeger H . Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay. PLoS One. 2008; 3(11):e3759. PMC: 2582436. DOI: 10.1371/journal.pone.0003759. View

12.

deVos T, Tetzner R, Model F, Weiss G, Schuster M, Distler J . Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem. 2009; 55(7):1337-46. DOI: 10.1373/clinchem.2008.115808. View

13.

Iacobucci I, Storlazzi C, Cilloni D, Lonetti A, Ottaviani E, Soverini S . Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute.... Blood. 2009; 114(10):2159-67. DOI: 10.1182/blood-2008-08-173963. View

14.

Shankar J, Messenberg A, Chan J, Underhill T, Foster L, Nabi I . Pseudopodial actin dynamics control epithelial-mesenchymal transition in metastatic cancer cells. Cancer Res. 2010; 70(9):3780-90. DOI: 10.1158/0008-5472.CAN-09-4439. View

15.

Vincent A, Omura N, Hong S, Jaffe A, Eshleman J, Goggins M . Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin Cancer Res. 2011; 17(13):4341-54. PMC: 3131423. DOI: 10.1158/1078-0432.CCR-10-3431. View

16.

Mead R, Duku M, Bhandari P, Cree I . Circulating tumour markers can define patients with normal colons, benign polyps, and cancers. Br J Cancer. 2011; 105(2):239-45. PMC: 3142810. DOI: 10.1038/bjc.2011.230. View

17.

Kibriya M, Raza M, Jasmine F, Roy S, Paul-Brutus R, Rahaman R . A genome-wide DNA methylation study in colorectal carcinoma. BMC Med Genomics. 2011; 4:50. PMC: 3135506. DOI: 10.1186/1755-8794-4-50. View

18.

Javierre B, Rodriguez-Ubreva J, Al-Shahrour F, Corominas M, Grana O, Ciudad L . Long-range epigenetic silencing associates with deregulation of Ikaros targets in colorectal cancer cells. Mol Cancer Res. 2011; 9(8):1139-51. DOI: 10.1158/1541-7786.MCR-10-0515. View

19.

Mouliere F, Robert B, Peyrotte E, Del Rio M, Ychou M, Molina F . High fragmentation characterizes tumour-derived circulating DNA. PLoS One. 2011; 6(9):e23418. PMC: 3167805. DOI: 10.1371/journal.pone.0023418. View

20.

Betge J, Pollheimer M, Lindtner R, Kornprat P, Schlemmer A, Rehak P . Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer. 2011; 118(3):628-38. DOI: 10.1002/cncr.26310. View